# China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population

> **NCT03314857** · NA · COMPLETED · sponsor: **Edwards Lifesciences** · enrollment: 67 (actual)

## Conditions studied

- Aortic Stenosis
- Symptomatic Aortic Stenosis
- Aortic Regurgitation

## Interventions

- **DEVICE:** SAPIEN XT THV with the NovaFlex+ delivery system

## Key facts

- **NCT ID:** NCT03314857
- **Lead sponsor:** Edwards Lifesciences
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-07-06
- **Final completion:** 2023-06-15
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314857, "China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03314857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*